Abstract
Aim:
Little is known about how integrated positron emission tomography-computed tomography (IPET-CT), both imaging tools and not methods of treatment, contributes to head and neck cancer patients’ outcomes. We analysed the clinical PET-CT findings and their correlation to the effects of applied contemporary disease management.
Methodology:
A retrospective analysis of 29 individuals who underwent treatment planning fusion of PET-CT for radiochemotherapy of locally advanced head and neck cancer between 2010 and 2016 was undertaken. Gross tumour volumes were categorised as small (≤36 cm3) or large (>36 cm3), and tumour responses to therapy were classified as complete or incomplete.
Results:
The overall rates of complete tumour response (CTR), 3-year crude survival and failure (all types included) were 80%, 41% and 55%, respectively. Comparative analysis of tumour volume subsets revealed no significant differences in the rates of CTR (p > 0.80), 3-year survival (p > 0.30) and locoregional recurrence (p > 0.70). CTR was associated with improved prognosis (p > 0.05) and fewer tumour relapses (p < 0.02).
Conclusion:
Our findings, although not truly conclusive, appear in line with those in the literature. Smaller tumour volumes and CTRs shown on integrated PET-CT are likely to play important roles in the promotion of better prognosis, but further study with larger patient numbers and more data are needed.
FDG-PET/CT as prognostic factor and surveillance tool for postoperative radiation recurrence in locally advanced head and neck cancer